Literature DB >> 21277534

Pathways to melanoma.

Justin M Ko1, Nicole F Velez, Hensin Tsao.   

Abstract

Melanoma is one of the most aggressive and yet poorly understood of human malignancies. Advances in genomics has allowed a more nuanced understanding of the disease, moving beyond the traditional dysplastic nevus-to-melanoma model and identifying multiple divergent oncogenic pathways leading to melanoma. An understanding of the molecular mechanisms driving melanoma has opened the doors for the development of targeted therapeutic approaches. As we enter the era of personalized medicine, it will be critical for clinicians to both appreciate and be able to determine the molecular profile of their patients' melanoma because this profile will guide risk stratification, genetic counseling, and treatment customization. A review of the divergent pathways of melanoma development is presented here, with a particular emphasis on recently identified mutations, and their implications for patient care.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21277534     DOI: 10.1016/j.sder.2010.10.004

Source DB:  PubMed          Journal:  Semin Cutan Med Surg        ISSN: 1085-5629


  9 in total

1.  The involvement of Notch signaling in melanoma vasculogenic mimicry.

Authors:  Amalia Vartanian; Galina Gatsina; Irina Grigorieva; Elico Solomko; Vladislav Dombrovsky; Anatoly Baryshnikov; Eugenia Stepanova
Journal:  Clin Exp Med       Date:  2012-05-25       Impact factor: 3.984

2.  Primary malignant melanoma of the pleura with rapid progression: A case report and literature review.

Authors:  Qiong Wang; Jing Chen; Meera Dassarath; Zhongyuan Yin; Xiuping Yang; Kunyu Yang; Gang Wu
Journal:  Oncol Lett       Date:  2015-04-08       Impact factor: 2.967

3.  Genetic and molecular characterization of uveal melanoma cell lines.

Authors:  K G Griewank; X Yu; J Khalili; M M Sozen; K Stempke-Hale; C Bernatchez; S Wardell; B C Bastian; S E Woodman
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-02       Impact factor: 4.693

Review 4.  Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance.

Authors:  William Wagstaff; Rimel N Mwamba; Karina Grullon; Mikhayla Armstrong; Piao Zhao; Bryce Hendren-Santiago; Kevin H Qin; Alexander J Li; Daniel A Hu; Andrew Youssef; Russell R Reid; Hue H Luu; Le Shen; Tong-Chuan He; Rex C Haydon
Journal:  Genes Dis       Date:  2022-04-27

Review 5.  Aetiology and Pathogenesis of Cutaneous Melanoma: Current Concepts and Advances.

Authors:  Strahil Strashilov; Angel Yordanov
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

6.  Comparison of the influence of photodynamic reaction on the Me45 and MEWO cell lines in vitro.

Authors:  Anna Choromańska; Jolanta Saczko; Julita Kulbacka; Iwona Kamińska; Nina Skołucka; Michał Majkowski
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06

7.  Comparison of c-Kit expression between primary and metastatic melanoma of skin and mucosa.

Authors:  Fatemeh Sari Aslani; Bita Geramizadeh; Amir Reza Dehghanian
Journal:  Med J Islam Repub Iran       Date:  2015-04-21

8.  Analysis of the B-RafV600E mutation in cutaneous melanoma patients with occupational sun exposure.

Authors:  Saverio Candido; Venerando Rapisarda; Andrea Marconi; Grazia Malaponte; Valentina Bevelacqua; Pietro Gangemi; Aurora Scalisi; James A McCubrey; Roberta Maestro; Demetrios A Spandidos; Concettina Fenga; Massimo Libra
Journal:  Oncol Rep       Date:  2014-01-14       Impact factor: 3.906

Review 9.  Preferentially Expressed Antigen in Melanoma (PRAME) and Human Malignant Melanoma: A Retrospective Study.

Authors:  Gerardo Cazzato; Katia Mangialardi; Giovanni Falcicchio; Anna Colagrande; Giuseppe Ingravallo; Francesca Arezzo; Giovanna Giliberti; Irma Trilli; Vera Loizzi; Teresa Lettini; Sara Scarcella; Tiziana Annese; Paola Parente; Carmelo Lupo; Nadia Casatta; Eugenio Maiorano; Gennaro Cormio; Leonardo Resta; Domenico Ribatti
Journal:  Genes (Basel)       Date:  2022-03-19       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.